financetom
Business
financetom
/
Business
/
Ecolab misses second-quarter profit estimates on reduced demand
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ecolab misses second-quarter profit estimates on reduced demand
Jul 29, 2025 6:34 AM

July 29 (Reuters) - Water solutions company Ecolab ( ECL )

on Tuesday posted an adjusted profit for the second

quarter that narrowly missed Wall Street estimates, hit by

reduced demand for its services that include cleaning,

sanitization and cooling.

Ecolab's ( ECL ) shares fell 2.88% to $262 in premarket trading.

The company forecast third-quarter adjusted profit between

$2.02 and $2.12 per share, the mid-point of which is in line

with analysts' estimate of $2.07 per share, according to data

compiled by LSEG data.

Ecolab ( ECL ) said that in the near-term, the global operating

environment remains unpredictable, characterized by constantly

evolving end-market demand and impacts from geopolitics and

international trade policy.

President Donald Trump's tariffs on U.S. trade partners and

the retaliatory levies from countries such as China have

threatened a rise in raw material costs for companies such as

Ecolab ( ECL ).

"I see little impact to Ecolab ( ECL ) from tariffs. They already

implemented surge pricing to account for tariffs, so any tariff

impacts should be more of a pass through cost for Ecolab ( ECL ),"

Morningstar analyst Seth Goldstein had said prior to the

earnings announcement.

Sales at the company's global institutional and specialty

segment, which makes cleaning and sanitizing products for

customers such as quick-serving restaurant chains and food

retailers, fell 2.4% to $1.51 billion in the second quarter,

from a year earlier.

However, sales from the global water unit, Ecolab's ( ECL ) biggest

segment that provides water treatment and cleaning solutions to

large industrial customers, rose 2.4% to $1.91 billion from last

year.

The Saint Paul, Minnesota-based company posted a profit of

$1.89 per share on an adjusted basis for the three months ended

June 30, compared with analysts' average estimate of $1.90.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Lead Real Estate to Open Extended-Stay Hotel in Tokyo
Lead Real Estate to Open Extended-Stay Hotel in Tokyo
Dec 9, 2024
03:54 AM EST, 12/09/2024 (MT Newswires) -- Lead Real Estate ( LRE ) said Sunday it will launch a new extended-stay apartment hotel in Ginza, Tokyo, on Dec. 16. All six guest rooms offer a safe and luxurious space with one room per floor, the company said. ...
Volkswagen, unions must find new solutions for German plants, company says
Volkswagen, unions must find new solutions for German plants, company says
Dec 9, 2024
WOLFSBURG, Germany (Reuters) - Volkswagen's chief negotiator Arne Meiswinkel said on Monday that unions and management needed to find alternative pathways to a solution for its German plants after the company rejected a proposal put forward by unions as unsustainable. We continue to need to reduce costs, reduce overcapacity, Meiswinkel said, speaking ahead of the fourth round of negotiations between...
MaxCyte Reduces 15% of Workforce, Raises 2024 Revenue Guidance
MaxCyte Reduces 15% of Workforce, Raises 2024 Revenue Guidance
Dec 9, 2024
04:05 AM EST, 12/09/2024 (MT Newswires) -- MaxCyte ( MXCT ) said Monday it has completed an operational review which resulted in a 15% reduction of its workforce, affecting 21 positions and saving about $5.8 million in 2025. The layoffs and other personnel decisions will bring its headcount to 116 employees by the end of 2024, compared with 143 at...
Genmab's Potential Leukemia Treatment Shows Overall Response Rate of 61% in Phase 1/2 Trial
Genmab's Potential Leukemia Treatment Shows Overall Response Rate of 61% in Phase 1/2 Trial
Dec 9, 2024
03:47 AM EST, 12/09/2024 (MT Newswires) -- Genmab ( GMAB ) said Sunday that results from a phase 1/2 clinical trial of epcoritamab showed an overall response rate of 61% and a complete response rate of 39% in difficult-to-treat adult patients with relapsed or refractory chronic lymphocytic leukemia. Among all patients treated with the subcutaneously administered T-cell engaging antibody, median...
Copyright 2023-2026 - www.financetom.com All Rights Reserved